A retrospective, Cross-sectional study on Ticagrelor usage pattern and tolerability in acute coronary syndrome (CROSS-TIC)

Acute Coronary Syndrome (ACS) is a life-threatening clinical condition resulting from acute myocardial ischemia, encompassing unstable angina (UA), non-ST-segment elevation myocardial infarction (NSTEMI) and ST-segment elevation myocardial infarction (STEMI). It is most commonly caused by atherosclerotic plaque rupture with subsequent thrombosis and platelet aggregation, necessitating prompt antiplatelet therapy. Dual antiplatelet therapy (DAPT), typically involving aspirin and a P2Y12 receptor inhibitor, is the cornerstone of ACS management. While clopidogrel is widely used, its limitations have led to the use of newer agents like prasugrel and ticagrelor.

This retrospective, clinic-based drug utilization study aims to assess the usage pattern and tolerability of ticagrelor in the management of ACS or in patients with a prior history of myocardial infarction. The study will analyze approximately 15,000 cases across India to better understand ticagrelor’s real-world application and impact in secondary cardiovascular event prevention. Data of male or female patients 18 years and above and patients with history of MI or diagnosed with ACS and treated with ticagrelor will be collected for the study.